中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
15期
2313-2314
,共2页
关节积液%炎症性关节炎%重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白%关节腔注射
關節積液%炎癥性關節炎%重組人Ⅱ型腫瘤壞死因子受體-抗體融閤蛋白%關節腔註射
관절적액%염증성관절염%중조인Ⅱ형종류배사인자수체-항체융합단백%관절강주사
oint effusion%Inflammatory arthritis%Recombinant human tumor necrosis factor-αreceptor Ⅱ%IgG Fc fusion protein%Intra-articular injection
目的 观察关节腔内注射重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)对顽固性膝关节积液的疗效及安全性.方法 对10例经传统方法处理后仍表现为顽固性膝关节积液的炎症性关节炎患者给予关节腔内注射益赛普(1.25 mg)治疗,于注射1周、2周后进行疗效和安全性评价.结果 治疗1、2周后总体有效率分别为60％、70％,患者和医生总体评分(视觉模拟标尺VAS 0～100 mm)、关节压痛和活动痛评分(VAS)均有明显改善,关节积液吸收,膝关节周径比基线期减低(均P＜0.05).结论 关节腔内注射益赛普对于改善患者顽固性膝关节积液是一种值得临床尝试的治疗方法.
目的 觀察關節腔內註射重組人Ⅱ型腫瘤壞死因子受體-抗體融閤蛋白(益賽普)對頑固性膝關節積液的療效及安全性.方法 對10例經傳統方法處理後仍錶現為頑固性膝關節積液的炎癥性關節炎患者給予關節腔內註射益賽普(1.25 mg)治療,于註射1週、2週後進行療效和安全性評價.結果 治療1、2週後總體有效率分彆為60％、70％,患者和醫生總體評分(視覺模擬標呎VAS 0～100 mm)、關節壓痛和活動痛評分(VAS)均有明顯改善,關節積液吸收,膝關節週徑比基線期減低(均P＜0.05).結論 關節腔內註射益賽普對于改善患者頑固性膝關節積液是一種值得臨床嘗試的治療方法.
목적 관찰관절강내주사중조인Ⅱ형종류배사인자수체-항체융합단백(익새보)대완고성슬관절적액적료효급안전성.방법 대10례경전통방법처리후잉표현위완고성슬관절적액적염증성관절염환자급여관절강내주사익새보(1.25 mg)치료,우주사1주、2주후진행료효화안전성평개.결과 치료1、2주후총체유효솔분별위60％、70％,환자화의생총체평분(시각모의표척VAS 0～100 mm)、관절압통화활동통평분(VAS)균유명현개선,관절적액흡수,슬관절주경비기선기감저(균P＜0.05).결론 관절강내주사익새보대우개선환자완고성슬관절적액시일충치득림상상시적치료방법.
Objective To evaluate the clinical efficacy and safety of the intra-articular injection of recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein (rhTNFR:Fc) in inflammatory arthritis patients with refractory knee effusion.Methods Ten inflammatory arthritis patients presented with refractory knee effusion after treatment of intra-articular steroid injection were involved.They received intra-articular injection rhTNFR:Fc (12.5mg twice weekly).The clinical efficacy and safety were assessed the first and second week after injection.Results At 1 week and 2 weeks,the total effective rate was 60％ and 70％ respectively.Patients and physicians global assessment score (visual analogue scale VAS 0-100mm),joint tenderness and movement pain scale (VAS) were significantly improved.Knee circumference was reduced as compared with baseline (all P ＜ 0.05).Conclusion Intra-artiular injection of rhTNFR:Fc in improving patients with refractory knee effusion is a worthwhile clinical treatment attempt.
